Amphastar Pharmaceuticals, Inc. (AMPH)

Over the past six months, Amphastar Pharmaceuticals' stock price has decreased by 19.14%. Key events include the company reporting its financial results for the three months and full year ended December 31, 2025, which led to a stock drop due to lowered FY26 revenue growth projections. Amphastar announced FDA approval for Ipratropium Bromide HFA inhalation aerosol with plans for an early second-quarter 2026 launch. The company also announced an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. In December 2025, the FDA approved Amphastar's teriparatide injection, and in August 2025, the FDA approved Amphastar's iron sucrose injection.

Demand seasonality for Amphastar Pharmaceuticals' products is evident in certain areas, such as Primatene MIST, where demand fluctuates with seasons due to asthma symptom prevalence. The company's strategy to scale high-value injectables aims to reduce single-product concentration risk, implying a recognition of varying demand across its portfolio.

Amphastar Pharmaceuticals is a biopharmaceutical company specializing in the development, manufacturing, marketing, and sale of technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin API. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. Its products are used in hospital or urgent care settings and distributed through group purchasing organizations and drug wholesalers. The business is divided into finished pharmaceutical products and API products, with major products including BAQSIMI, Primatene MIST, epinephrine, and others. Amphastar has a pipeline of over 20 product candidates.

Amphastar Pharmaceuticals has a business presence in the United States, China, and France, with the U.S. accounting for the majority of its revenue. Its headquarters and a significant portion of its sterile injectables cGMP manufacturing are located in Rancho Cucamonga, California. Other U.S. facilities include IMS in South El Monte, California, and Armstrong Pharmaceuticals in Canton, Massachusetts. Additionally, ANP in Nanjing, Jiangsu Province, China, is an FDA-registered manufacturer of active pharmaceutical ingredients and intermediates.

Amphastar Pharmaceuticals' brand reputation is influenced by its commitment to domestic pharmaceutical manufacturing and strengthening supply chain resilience. The company faces scrutiny regarding compliance with laws and regulations concerning privacy, security, and protection of employee data. The transition from generics to a proprietary pipeline presents challenges such as declining legacy generics and growth deceleration in branded products.

Amphastar Pharmaceuticals, Inc. is primarily owned by institutional shareholders and insiders. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and TD Asset Management Inc. Key individual owners include Jack Y. Zhang, who is the largest individual shareholder, and Mary Z. Luo.